Valuation : BioNxt Solutions Inc.

Market Cap 48.98M 35.33M 30.33M 28.39M 26M 3.37B 49.12M 336M 131M 1.7B 133M 130M 5.63B P/E 2024
-7.97x
P/E 2025 -10.8x
Enterprise Value 54.87M 39.58M 33.98M 31.81M 29.13M 3.78B 55.03M 377M 147M 1.91B 149M 145M 6.31B EV / Sales 2024
1,754x
EV / Sales 2025 -
Free-Float
94.6%
Yield 2024 *
-
Yield 2025 -
1 day+5.88%
1 week+4.35%
Current month+20.00%
1 month+18.03%
3 months-19.10%
6 months-40.00%
Current year-43.75%
1 week 0.3
Extreme 0.3
0.38
1 month 0.3
Extreme 0.3
0.38
Current year 0.28
Extreme 0.28
0.69
1 year 0.28
Extreme 0.28
1.04
3 years 0
Extreme 0
1.1
5 years 0
Extreme 0
1.74
10 years 0
Extreme 0
3.55
Manager TitleAgeSince
Chief Executive Officer 45 2017-12-11
Chief Executive Officer 46 2017-12-11
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2017-12-11
Director/Board Member 60 2018-12-09
Director/Board Member 45 2017-12-11
Date Insider Type Main position Quantity % Market Cap.
7/31/26 Option

Director

100,000 0.0769%
7/31/26 Option

Chief Financial Officer

100,000 0.0769%
7/31/26 Option

Founder

650,000 0.5000%
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+4.35%-64.36%-5.26% 33.31M
-1.12%-5.49%+60.19%+112.43% 1,060B
-1.57%-0.60%+50.33%+59.86% 651B
-1.81%-1.41%+24.07%+75.98% 465B
-1.17%-2.10%+38.61%+40.43% 365B
-2.00%-1.35%+22.22%+38.92% 300B
-0.98%+0.53%+2.04%+12.13% 258B
-0.76%+0.75%+51.75%+70.45% 238B
-3.18%-0.30%-17.23%-53.79% 210B
+0.52%+3.78%+30.67%+93.68% 184B
Average -0.62%-0.21%+19.83%+44.48% 373.04B
Weighted average by Cap. -1.36%-1.46%+38.43%+65.86%

Financials

2024 2025
Net sales 26.98K 19.47K 16.71K 15.64K 14.32K 1.86M 27.06K 185K 72.42K 937K 73.08K 71.51K 3.1M -
Net income -5.31M -3.83M -3.29M -3.08M -2.82M -366M -5.33M -36.46M -14.25M -184M -14.39M -14.07M -610M -7.03M -5.07M -4.35M -4.07M -3.73M -484M -7.05M -48.23M -18.85M -244M -19.03M -18.62M -807M
Net Debt 4.25M 3.06M 2.63M 2.46M 2.25M 293M 4.26M 29.16M 11.4M 147M 11.5M 11.26M 488M 5.89M 4.25M 3.65M 3.42M 3.13M 406M 5.91M 40.44M 15.81M 205M 15.96M 15.61M 677M
Logo BioNxt Solutions Inc.
BioNxt Solutions Inc. is a Canada-based bioscience company. The Company focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
Employees
-
Date Price Change Volume
26-08-27 $0.3600 +5.88% 18,500
26-08-26 $0.3400 +3.03% 53,634
26-08-25 $0.3300 -1.49% 54,250
26-08-24 $0.3350 -1.47% 9,250
26-08-21 $0.3400 -1.45% 100,500
  1. Stock Market
  2. Stocks
  3. BNXT Stock